Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dual Therapy With Raltegravir 400 mg BID and Darunavir/Ritonavir 800/100 mg QD in HIV Infected Patients Failing to Nucleoside Reverse Transcriptase Inhibitors Based Regimens

NCT01258374 is registered in ClinicalTrials.gov with Hospital Clinic of Barcelona as lead sponsor.

NCT NCT01258374
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01258374 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dual Therapy With Raltegravir 400 mg BID and Darunavir/Ritonavir 800/100 mg QD in HIV Infected Patients Failing to Nucleoside Reverse Transcriptase Inhibitors Based Regimens
Lead sponsor
Hospital Clinic of Barcelona
Phase
Observational
Overall status
Completed
Start date
May 31, 2010
Completion date
December 31, 2011
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

integrase inhibitors, hiv; hiv protease inhib